When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance across sophisticated facilities. It is easy to conclude that life sciences compliance itself has become the problem.
However, inspections rarely create operational issues; rather, they expose them. Whether a finding involves incomplete maintenance records, overdue calibration, inconsistent training documentation, missing environmental monitoring data, or conflicting equipment information, the underlying problem usually isn’t the regulation; it is that operational processes have become fragmented, disconnected, or overly dependent on manual effort.
That distinction is especially important in life sciences, where product quality, patient safety, and regulatory compliance are closely connected. The U.S. Food and Drug Administration describes Current Good Manufacturing Practice (CGMP) as a system for ensuring the proper design, monitoring, and control of manufacturing processes and facilities, not simply a collection of documentation requirements.[1] Compliance becomes the natural outcome of good operations, not a separate activity layered on top of them.
Inspections Expose Operational Reality
Few facilities spend the entire year operating in “inspection mode.” Instead, several weeks before an expected regulatory inspection, customer audit, or certification review, priorities suddenly shift.
Maintenance teams begin searching for work histories, calibration certificates, and preventive maintenance records. Supervisors verify employee training records. Engineering departments locate equipment specifications and change-control histories, while quality teams review deviations, corrective and preventive actions, inspection logs, and standard operating procedures.
The scramble may succeed, and the facility may pass the inspection. But the inspection did not create the disruption; it revealed that critical operational information was not readily available when needed. If records must be reconstructed or multiple departments contacted to confirm routine activities, the organization is experiencing an operational visibility problem as much as a compliance problem.
FDA inspection data illustrate how frequently inspectors identify conditions requiring attention within the inspected population. Of the 1,309 pharmaceutical manufacturing inspections included in the agency’s fiscal year 2025 data, only 22% resulted in “no action indicated.” Sixty percent resulted in “voluntary action indicated,” meaning objectionable conditions were found but did not warrant regulatory action. Another 18% resulted in “official action indicated,” meaning regulatory or administrative action was recommended.[2]
The consequences can extend beyond an unfavorable inspection. Incomplete or conflicting information can delay batch release, complicate deviation investigations, weaken root-cause analysis, and raise questions about whether equipment remained in a qualified state. Preventive maintenance and improvement initiatives may also be delayed while employees spend time locating and reconciling records instead of solving problems.
Compliance Is Not a Separate Operational System
One reason organizations struggle is that life sciences compliance is frequently treated as its own function:
- Manufacturing manages production and batch execution.
- Maintenance manages equipment reliability.
- Engineering manages equipment and facility changes.
- Quality manages inspections and deviations.
- Validation manages qualification and validated systems.
- Laboratory teams manage testing and analytical records.
Each function has legitimate responsibilities, yet the work is deeply interconnected. Preventive maintenance improves equipment reliability while helping preserve its qualified state. Calibration supports accurate process control. Operator training builds workforce competency while meeting qualification requirements. And asset records support both maintenance planning and investigations.
None of these activities exists solely because of compliance; they exist because safe and reliable life sciences operations require them. Problems emerge when organizations manage these activities as separate administrative exercises. Maintenance may record a repair in one platform while quality documents the related deviation elsewhere. Engineering may maintain equipment specifications separately from the records used by technicians. Calibration, validation, and change-control information may reside in different systems with inconsistent asset names or identification numbers.
Employees then enter the same information in multiple places, while departments maintain competing versions of the same records. Managers spend time reconciling discrepancies instead of making better operational decisions. Life sciences compliance begins to feel like an additional burden, even though much of that burden was created by disconnected processes.
The World Health Organization’s definition of Good Manufacturing Practice reinforces the connection between compliance and daily operations. It specifies that pharmaceutical production and testing processes should be clearly defined, validated, reviewed, and documented and that the personnel, premises, and materials should be suitable for their intended purposes.[3]
These are not isolated regulatory technicalities; they are fundamental operational disciplines.
Is Operational Complexity Self-Inflicted?
Life sciences companies clearly operate in demanding regulatory environments. But many organizations unintentionally create more complexity than regulations require. Processes evolve over many years. New approval steps are introduced following deviations, audit findings, or isolated incidents. Additional spreadsheets supplement existing systems. Departments develop their own tracking methods while older procedures remain in place after their original purpose has faded.
The result is an environment in which employees spend growing amounts of time navigating internal procedures instead of executing the work those procedures were designed to support. These additional layers may do little to strengthen compliance; rather, they create opportunities for duplicate effort, delayed decisions, incomplete records, and procedural deviations.
Technology can help, but digitizing a fragmented process does not necessarily correct it. Automating inconsistent workflows can simply allow poor practices to operate faster.
Many organizations discover that their biggest gains come from simplifying existing processes: eliminating redundant approvals, clarifying ownership, removing obsolete steps, and aligning workflows across departments. These improvements reduce administrative effort while strengthening operational control.
Growth Magnifies Operational Weaknesses
Processes that work reasonably well at one facility often begin to break down as life sciences organizations grow. A second manufacturing site introduces new equipment, production lines, and maintenance teams. An acquisition may bring different quality systems and asset hierarchies. Geographic expansion introduces additional regulatory jurisdictions, while new products create further qualification, validation, calibration, and training requirements.
The challenge is not simply that there is more compliance work; the problem is that processes designed for a smaller organization frequently do not scale. Manual coordination becomes increasingly difficult, ownership becomes less clear, and practices may vary from one facility to another.
Leaders may conclude that the organization has developed a compliance problem. More accurately, it has outgrown its operational processes. Addressing the problem requires more than additional administrative effort; it requires processes and responsibilities designed to work across the larger organization.
Operational weaknesses can also interfere directly with bringing products to market. The FDA analyzed nearly 10,000 drug applications and supplements requiring facility assessments during fiscal years 2024 and 2025. As of May 2026, 28% had received Complete Response Letters, meaning they could not be approved in their existing form. Of those letters, 43% (representing 12% of all submissions examined) were attributable to facility withholds. More than half of those withholds involved facilities with pre-existing or potential “official action indicated” status.[4]
The data suggest that operational and compliance weaknesses at manufacturing facilities may contribute to approval delays, disrupt launch planning, and postpone access to products. The FDA noted that many of those Complete Response Letters might have been prevented if the submissions had included only facilities with compliant inspection status.
Regulatory readiness therefore cannot begin shortly before an inspection or product submission. It depends on consistently applied operational controls, documented processes, and reliable execution throughout the product lifecycle.
Compliance and Operations Align
Perhaps the biggest misconception surrounding life sciences compliance is that it competes with operational performance. In reality, both depend on the same fundamentals:
- Reliable equipment requires disciplined maintenance and calibration.
- Consistent product quality requires controlled processes.
- Patient safety depends on effective quality controls.
- Qualified facilities require coordination among maintenance, engineering, validation, and change management.
- Operational resilience requires clear accountability.
Regulators evaluate whether these disciplines are controlled and consistently practiced. Yet organizations sometimes focus on improving inspection outcomes without addressing the conditions that caused the findings. If maintenance information remains fragmented and responsibilities are unclear, quality teams are left compensating for weaknesses they do not control.
Quality cannot inspect compliance into an operation after the work has been completed. The necessary controls must be embedded in how work is planned and executed.
Looking Beyond the Inspection
Regulatory expectations will continue to evolve. Life sciences organizations should expect ongoing scrutiny of data integrity, computerized systems, supply-chain resilience, contamination control, workforce competency, cybersecurity, and the continued suitability of facilities and equipment.
The solution is not simply to work harder every time another requirement is introduced. Organizations should instead determine whether the way work is performed provides the control needed to support product quality, operational performance, and regulatory compliance.
When inspections uncover gaps, overdue activities, or incomplete evidence, organizations should ask what those findings reveal about everyday operations. After all, inspections do not create operational weaknesses; they simply make them visible. And when those underlying weaknesses are addressed, compliance stops being a periodic scramble. It becomes the natural result of an organization that is being run effectively.
Author Bio















